Nexentis Technologies Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NITO research report →
Price Chart
About the company
Nexentis Technologies Inc. develops and operates an AI and data-driven computational biotech platform. It focuses on mitochondrial biology, precision oncology, and inflammatory metabolic diseases.
- CEO
- David Palach
- IPO
- 2022
- Employees
- 9
- HQ
- Meshek Sander Neve Yarak, IL, IL
Get TickerSpark's AI analysis on NITO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.92M
- P/E
- -0.08
- PEG
- 0.00
- P/S
- -1.54
- P/B
- 0.77
- EV/EBITDA
- 0.82
- Div Yield
- 0.00%
- Gross Margin
- 268.18%
- Op Margin
- 17754.55%
- Net Margin
- 24283.33%
- ROE
- -161.01%
- ROIC
- -72.45%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-79,000-275.6%
- Op Income
- $-5,029,000
- Net Income
- $-4,004,000+22.9%
- EPS
- $-3.54+88.6%
- OCF Growth
- -11.4%
- FCF Growth
- -11.4%
- 52W High
- $29.40
- 52W Low
- $0.57
- 50D MA
- $1.49
- 200D MA
- $5.36
- Beta
- 1.85
- RSI (14)
- 39
- Avg Volume
- 1.13M
No earnings-call transcripts are available for NITO yet.
- Free Float
- 59.8%
- Shares Outstanding
- 953.03K
- Float Shares
- 570.01K
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 9, 26 | Zakai Shlomo | other | 50,000 |
| Feb 9, 26 | Barda Lital | other | 50,000 |
| Feb 9, 26 | Weiss Amitay | other | 116,286 |
| Feb 9, 26 | Palach David | other | 100,000 |
| Oct 20, 25 | Silberman Alon | other | 0 |
| Oct 20, 25 | Silberman Alon | other | 146,493 |
| Oct 20, 25 | SciSparc Ltd. | other | 0 |
| May 12, 25 | Barda Lital | other | 300,000 |
| May 12, 25 | Palach David | other | 600,000 |
| Dec 23, 24 | Rosenbloom Ronen | buy | 50,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NITO coverage
Recent articles, reports, and earnings notes.
No research on NITO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NITO report →Forafric Global (NASDAQ:AFRI) & N2OFF (NASDAQ:NITO) Financial Contrast
defenseworld.net · Mar 23
N2OFF (NASDAQ:NITO) Shares Up 5.4% – Still a Buy?
defenseworld.net · Mar 4
N2OFF Announcing Corporate Rebranding as Nexentis Technologies - Innovative AI and Data Driven Computational Biotech Company
globenewswire.com · Feb 25
N2OFF, Inc. Provides Early Warning Disclosure
thenewswire.com · Feb 19
In Spaceflight Conditions: N2OFF‘s MitoCareX Bio Highlights Co-Founder's Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions
globenewswire.com · Feb 2
N2OFF: MitoCareX Bio Announces Positive In Vitro Results from Its Mitochondrial Carrier Small Molecule Platform
globenewswire.com · Jan 22
N2OFF: MitoCareX Bio Spotlights Co-Founder's Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions
globenewswire.com · Jan 15
N2OFF Advances $340,000 Payment to Gain Better Terms in Flag Solar Energy Initiative, Reflecting Approximately an Additional $1.7 Million in Project Profit Stake
globenewswire.com · Jan 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.